The KID team in Stockholm was the first in Sweden to offer gender identity investigations for children and young people.

They opened in 2000 and over 700 young people have been investigated for gender dysphoria.

Diagnosed patients have been able to receive hormone treatment at Karolinska Hospital.

In several reports, Assignment Review has highlighted the lack of scientificity and the risks of the various hormone treatments.

These are strong preparations that can have serious and irreversible health effects.

In the spring of 2019, the KID team's founder, Per-Anders Rydelius, defended the treatment:

-The treatment is not experimental in the sense of the word.

It follows an investigation model that has been tested.

Potential side effects

Karolinska's new guidelines now stack the potential side effects on top of each other: cardiovascular disease, osteoporosis, infertility, cancer and thrombotic disease.

The hospital also writes that the treatment has low evidence of achieving the desired effect and that today there is very little knowledge about safety in the long term.

Another aspect is the risk of remorse.

In the UK, a young woman, who today regrets her hormone treatment, has started a lawsuit against healthcare.

This has led to a court in principle stopping the use of puberty blockers and sex-opposite hormones in people under 18 years of age.

In Assignment Review 2019, women who had regretted their gender-confirming treatment appeared.

Several were very critical of the care, which they believed had not taken their responsibility.

Entered into force on 1 May

- The care does not know what they are doing.

They have no science behind this.

They are trying on a young generation that has their whole life ahead of them.

I do not know of any other area in medicine where one tries a treatment in this way, said 'Mika', who lives with the consequences of an irreversible hormone treatment.

The new guidelines came into force on 1 May and mean that no new minors will receive hormone treatment, other than within the framework of clinical studies.

For patients already undergoing treatment, physicians should make a 'careful individual assessment of whether treatment should be discontinued or continued.'